» Articles » PMID: 33804536

Food, Nutrition, Physical Activity and Microbiota: Which Impact on Lung Cancer?

Overview
Publisher MDPI
Date 2021 Apr 3
PMID 33804536
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer still represents the leading cause of cancer-related death, globally. Likewise, malnutrition and inactivity represent a major risk for loss of functional pulmonary capacities influencing overall lung cancer severity. Therefore, the adhesion to an appropriate health lifestyle is crucial in the management of lung cancer patients despite the subtype of cancer. This review aims to summarize the available knowledge about dietary approaches as well as physical activity as the major factors that decrease the risk towards lung cancer, and improve the response to therapies. We discuss the most significant dietary schemes positively associated to body composition and prognosis of lung cancer and the main molecular processes regulated by specific diet schemes, functional foods and physical activity, i.e., inflammation and oxidative stress. Finally, we report evidence demonstrating that dysbiosis of lung and/or gut microbiome, as well as their interconnection (the gut-lung axis), are strictly related to dietary patterns and regular physical activity playing a key role in lung cancer formation and progression, opening to the avenue of modulating the microbiome as coadjuvant therapy. Altogether, the evidence reported in this review highlights the necessity to consider non-pharmacological interventions (nutrition and physical activity) as effective adjunctive strategies in the management of lung cancer.

Citing Articles

Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature).

Smolarz B, Lukasiewicz H, Samulak D, Piekarska E, Kolacinski R, Romanowicz H Int J Mol Sci. 2025; 26(5).

PMID: 40076671 PMC: 11900952. DOI: 10.3390/ijms26052049.


Exposure to major coronary heart disease events reduces lung cancer risk: a mendelian randomization study based on a European population.

He D, Lu H, Ou X, Zheng T, Zheng Z, Xu Z BMC Cancer. 2025; 25(1):152.

PMID: 39871145 PMC: 11770941. DOI: 10.1186/s12885-025-13485-6.


The Effect of Nutritional Intervention in Nutritional Risk Screening on Hospitalised Lung Cancer Patients.

Oliveira R, Cabrita B, Cunha A, Silva S, Lima J, Martins D Nutrients. 2025; 17(1.

PMID: 39796440 PMC: 11723048. DOI: 10.3390/nu17010006.


Charting cancer's course: revealing the role of diet, exercise, and the microbiome in cancer evolution and immunotherapy response.

Martin-Quesada A, Hennessy M, Gutierrez A Clin Transl Oncol. 2024; 27(2):473-485.

PMID: 39095683 PMC: 11782318. DOI: 10.1007/s12094-024-03595-1.


[Application of Precision Nursing Based on Multidisciplinary Collaboration Model in Older Patients Undergoing Thoracoscopic Surgery for Lung Cancer].

Mei S, Wu X, Yang J, Yu Z, Jiang Y, Xue Y Sichuan Da Xue Xue Bao Yi Xue Ban. 2023; 54(5):1052-1057.

PMID: 37866968 PMC: 10579088. DOI: 10.12182/20230960508.


References
1.
Marmot M . Diet, cancer, and NCD prevention. Lancet Oncol. 2018; 19(7):863-864. DOI: 10.1016/S1470-2045(18)30382-6. View

2.
Enoki Y, Watanabe H, Arake R, Sugimoto R, Imafuku T, Tominaga Y . Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci Rep. 2016; 6:32084. PMC: 4994088. DOI: 10.1038/srep32084. View

3.
Wang J, Yang H, Wang D, Wang X . Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors. Oncol Lett. 2020; 20(6):342. PMC: 7583737. DOI: 10.3892/ol.2020.12205. View

4.
Kuehr L, Wiskemann J, Abel U, Ulrich C, Hummler S, Thomas M . Exercise in patients with non-small cell lung cancer. Med Sci Sports Exerc. 2013; 46(4):656-63. DOI: 10.1249/MSS.0000000000000158. View

5.
Patel P, Alrifai D, McDonald F, Forster M . Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited). Br J Cancer. 2020; 123(Suppl 1):18-27. PMC: 7735213. DOI: 10.1038/s41416-020-01071-5. View